Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

格隆汇1月28日丨泰凌医药(01011.HK)公告，受中国医药行业发展新趋势及产业政策改革影响，公司董 事会从2020年起开始陆续处置集团的医药工业重资产，从而转向发展人工智能轻资产营运的医疗健康新 业态并据此制定系列发展战略。 公司有条件同意购买目标公司100%已发行股份，实际相当于最终控制中国经营公司(浙江康源医疗器械 有限公司*)约58.11%股权。收购完成后，集团将可整合中国经营公司所拥有之X射线机器人骨密度系 统、可携式数字X射线诊断机器人系统等核心AI诊断产品，与其12项专利和25个原代码，丰富集团在骨 健康人工智能诊断与医疗影像技术领域的产品线与核心竞争力，以此拓展人工智能(AI)骨健康诊断和检 测机器人业务。 (ii)骨健康领域「治疗」业务集团在骨科药物的代理收入及骨科健康产品的销售收入已达到稳定预期， 为集团的财务表现提供了稳定的贡献。 (iii)骨健康领域「康健」业务集团于2025年5月与中国某间国营央企合作共建智慧健康管理中心，该业务 将为客户提供定制化健康管理服务。预计自2026年起可为公司贡献稳定的收入来源。同时，集团已与中 国某间健康管理企业达成合作，为其提供数字健康服务并收取稳定 ...

格隆汇1月28日丨三鑫医疗(300453.SZ)在互动平台表示，公司是面向全球市场的医疗器械研发、制造、 销售及服务的国家高新技术企业，现有产品涵盖血液净化、给药器具、心胸外科三大领域，并向血管介 入、糖尿病等领域拓展。公司目前暂无脑机接口（人脑工程）相关领域的布局。 ...

Core Viewpoint - The company, Weili Medical, has reported a significant decline in the operating performance of its wholly-owned subsidiary, Jiangxi Langhe Medical Equipment Co., Ltd. (referred to as "Langhe Medical"), due to a slowdown in product market demand and intense industry competition [2] Group 1: Company Performance - The operating performance of Langhe Medical has been severely impacted, leading to a substantial decline in its financial results [2] - Weili Medical acquired 100% of Langhe Medical's shares in 2018, resulting in goodwill amounting to 26,936.70 million yuan [2] - The management has preliminarily assessed that the goodwill from the acquisition shows signs of impairment based on the current operating conditions and future forecasts [2] Group 2: Financial Adjustments - To reflect the company's financial status and asset value more objectively, it plans to recognize a goodwill impairment of 14,700 million yuan for the fiscal year 2025 [2] - The final impairment amount will be determined after evaluation and audit by appointed assessment and auditing agencies [2]

Core Viewpoint - The company, Weili Medical, is expanding its production capacity in Indonesia, focusing on medical products primarily for the U.S. market [1] Group 1: Production Capacity - The first phase of the Indonesian factory is designed to produce 40 million units of nursing products, specifically suction connection tubes with attract heads, all intended for a major U.S. client [1] - The second phase of production will include anesthetic products such as tracheal tubes and laryngeal masks, as well as urinary products like silicone catheters, also aimed at the U.S. market [1] Group 2: Future Plans - The company plans to adjust its production capacity for other anesthetic, urinary, and nursing products based on local market demand in Indonesia and the status of its overseas business expansion [1]

Core Viewpoint - The company has maintained a prudent approach to foreign exchange management, which minimizes the impact of currency fluctuations on overall performance [1] Group 1: Foreign Exchange Management - The company conducts regular settlements of foreign currencies and implements robust measures to mitigate exchange rate risks [1] - A portion of the overseas major clients conducts business transactions in Renminbi, further reducing the impact of currency volatility [1] - Overall, the influence of exchange rate fluctuations on the company's performance is generally limited [1]

Core Viewpoint - Tianzhihang (688277.SH) expects a net loss attributable to shareholders of the parent company for the fiscal year 2025, projected to be between 165 million and 198 million yuan, indicating an increase in losses compared to the same period last year [1] Summary by Relevant Categories Financial Performance - The anticipated net loss for 2025 is between 165 million and 198 million yuan, which represents an expansion of losses compared to the previous year [1] - The main reasons for the performance change include a significant decrease in investment income and an increase in share-based payment expenses due to the implementation of a restricted stock incentive plan [1] Taxation Impact - The increase in income tax expenses is attributed to the reversal of previously recognized losses, which has led to higher deferred tax expenses [1]

格隆汇1月28日丨奕瑞科技(688301.SH)公布2025年度业绩快报，报告期内，公司实现营业收入22.99亿 元，同比增加25.53%；实现归属于母公司所有者的净利润6.61亿元，同比增加42.15%，主要数字化X线 探测器业务平稳增长，综合解决方案及核心部件业务大幅增长所致；实现归属于母公司所有者的扣除非 经常性损益的净利润6.27亿元，同比增加42.89%。 归属于母公司所有者的净利润较上年同期增长42.15%，归属于母公司所有者的扣除非经常性损益的净 利润同比增长42.89%，主要原因系2025年营业收入较上年持续提升，同时公司继续专注于精益生产和 管理，毛利率和净利率保持在较高水准，相关利润指标较上年有大幅增长。 ...

北京商报讯1月28日晚间，三诺生物（300298）发布2025年业绩预告显示，预计2025年实现归属净利润 8500万元至12750万元，比上年同期下降60.92%至73.95%。 三诺生物表示，报告期内，公司全资子公司Polymer Technology Systems,Inc.（以下简称"PTS公司"）经 营业绩未达预期。结合PTS公司实际经营状况、行业市场变化和预期经营情况，经公司根据谨慎性原则 初步判断，对收购PTS公司所形成的商誉计提部分减值，预计本期计提的商誉减值总额为1.3亿元至1.7 亿元。 （文章来源：北京商报） ...

（文章来源：北京商报） 三友医疗表示，2025年，超声骨刀业务在销售业绩和净利润上均取得了快速的增长。公司国际化业务亦 保持持续快速发展，2025年，公司控股公司Implanet实现营业收入1247.39万欧元，同比增长32.62%，其 中美国市场表现优异，同比增长49.3%。 北京商报讯1月28日晚间，三友医疗（688085）发布2025年业绩预告显示，预计2025年实现归属净利润 5600万元到7280万元，与上年同期（法定披露数据）相比，预计将增加4453.14万元到6133.14万元，同 比增加388.29%到534.78%。 ...